Trials / Withdrawn
WithdrawnNCT02746328
Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GTx · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a multiple site, proof of concept feasibility study to describe the effect of GTx-024 9 or 18 mg on physical function in female subjects, from protocol G200802, with ER+/AR+ breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GTx-024 9 or 18 mg | Patients enrolled in G200802 receiving GTx-024 9 or 18 mg |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2018-02-01
- Completion
- 2018-02-01
- First posted
- 2016-04-21
- Last updated
- 2024-02-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02746328. Inclusion in this directory is not an endorsement.